Brittani Seynnaeve
Assistant Professor, Associate Pediatric Hematology/Oncology Fellowship Director, Pediatric Melanoma Program Director
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (3)
Limited information is available on the clinicopathologic features and management of pediatric CRTC1::TRIM11 (CTRTs) and MED15::ATF1 ‐rearranged tumors (MARTs). In this series of pediatric CTRTs ( n = 5) and MARTs ( n = 2), all tumors exhibited spitzoid morphology and expressed melanocytic markers. Metastatic progression occurred in one CTRT and two MARTs: all three received immunotherapy, resulting in disease control in two patients and one death due to progressive disease. A fourth individual had lymph node micrometastasis that remained stable without progression. This case series highlights the potentially aggressive behavior of these tumors and suggests that immunotherapy may be an effective treatment option for advanced disease.
Year:
2025
Year:
2024
Year:
2024
Collaborators (3)
Alberto Pappo
Member
St. Jude Children's Research Hospital
Michael Sargen
Lasker Clinical Research Scholar
National Cancer Institute
Stephen Hewitt
Editor-in-Chief
National Cancer Institute
Make your next move.
Prepare your application
Review drafts before you send them.